Geron (GERN) Accounts Payables (2010 - 2026)
Geron (GERN) posted Accounts Payables of $12.7 million for Q1 2026, up 13.0% sequentially from $11.3 million in Q4 2025, and up 58.37% YoY from $8.0 million in Q1 2025.
Geron (GERN) Accounts Payables (2010 - 2026) Analysis & Trends
Geron has reported Accounts Payables for 17 years, with the latest figure at $12.7 million in Q1 2026.
- Quarterly Accounts Payables rose 58.37% year-over-year to $12.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.7 million (up 58.37% YoY) and the FY2025 annual result came in at $11.3 million, up 30.97% from the prior year.
- Accounts Payables climbed to $12.7 million in Q1 2026 per GERN's latest filing, from $11.3 million in the prior quarter.
- Over five years, Accounts Payables peaked at $13.7 million in Q3 2024 and troughed at $3.4 million in Q1 2023.
- A 5-year average of $8.8 million and a median of $8.2 million in 2025 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables tumbled 45.83% in 2023, then soared 195.36% in 2024.
- Over 5 years, Accounts Payables stood at $10.2 million in 2022, then slumped by 39.54% to $6.2 million in 2023, then surged by 39.51% to $8.6 million in 2024, then jumped by 30.97% to $11.3 million in 2025, then advanced by 13.0% to $12.7 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $12.7 million, $11.3 million, and $11.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | 8.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.81 Mn |
| Mar 31, 2026 | 12.72 Mn |
| Dec 31, 2025 | 11.26 Mn |
| Sep 30, 2025 | 11.11 Mn |
| Jun 30, 2025 | 8.23 Mn |
| Mar 31, 2025 | 8.03 Mn |
| Dec 31, 2024 | 8.60 Mn |
| Sep 30, 2024 | 13.73 Mn |
| Jun 30, 2024 | 5.62 Mn |
| Mar 31, 2024 | 9.99 Mn |
| Dec 31, 2023 | 6.16 Mn |
| Sep 30, 2023 | 13.68 Mn |
| Jun 30, 2023 | 7.67 Mn |
| Mar 31, 2023 | 3.38 Mn |
| Dec 31, 2022 | 10.19 Mn |
| Sep 30, 2022 | 8.18 Mn |
| Jun 30, 2022 | 4.52 Mn |
| Mar 31, 2022 | 6.25 Mn |
| Dec 31, 2021 | 6.69 Mn |
| Sep 30, 2021 | 4.71 Mn |